Terminology and classification
In contradistinction to 'secondary' or 'reactive' hypereosinophilia, FIP1L1-PDGFRA-positive chronic eosinophilic leukemia (CEL) and other molecularly defined myeloproliferative neoplasms (MPNs) are broadly categorized as either 'primary' or 'clonal' eosinophilias, because they are acquired hematopoietic stem cell or progenitor cell marrow disorders for which a specific genetic abnormality has been identified. 1 CEL has also been defined by an increase in peripheral blood (42%) or bone marrow (45%) blasts in the absence of a clonal marker by conventional cytogenetic assays, fluorescence in situ hybridization (FISH) or other types of molecular studies (for example, X-chromosome inactivation analysis). 1 In addition, eosinophiliaassociated acute or chronic myeloid neoplasms must be excluded (for example, chronic myeloid leukemia (CML), acute myeloid leukemia (AML) (for example, French-American-British subtype M4Eo, inversion 16), myelodysplastic syndrome, systemic mastocytosis and so on). Although not formally adopted in the nomenclature of the World Health Organization (WHO), the term 'myeloproliferative variant of hypereosinophilic syndrome (M-HES)' has been commonly used in the literature to refer to these marrow-derived eosinophilic MPNs because they share one or more clinical or laboratory features suggestive of CML or the classic MPDs: hepato/splenomegaly, bone marrow hypercellularity or fibrosis, myeloid immaturity and elevated serum B12 or serum tryptase levels. 2 Lymphocyte-variant hypereosinophilia relates to the existence of clonal, pathogenetic T-cell subsets with an aberrant surface immunophenotype (for example, CD3
, which overproduce eosinophilopoietic cytokines such as interleukin-5 (IL-5) and other Th2 cytokines such as IL-4, IL-13 and granulocyte macrophage colonystimulating factor. 3, 4 In these cases, the eosinophilia is nonclonal. In rare instances, transformation of the clonal T cells to T-cell lymphoma has been reported, although lymphocytevariant hypereosinophilia generally follows a benign course. The diagnosis of idiopathic hypereosinophilic syndrome (HES) should be reserved for patients in whom no clonal marker has been identified, no increased blood or marrow blasts are present and for which no definite or suggestive clinical or laboratory features of a myeloproliferative or lymphocyte variant of hypereosinophilia can be found. 1 According to the classic definition of Chusid et al., 5 patients with idiopathic HES should also have an absolute eosinophil count of 41500/mm 3 and signs or symptoms of organ involvement; however, the requirement that the eosinophilia persist for 46 months has generally fallen out of favor, in part because some patients may require more urgent treatment, and modern diagnostic evaluations can proceed in a more timely manner. Table 1A and B highlight the 2001 WHO classification of chronic eosinophilic leukemia and HES and the revised 2008 WHO classification of 'myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1' as well as 'chronic eosinophilic leukemia, not otherwise specified (NOS).' 1, 6, 7 Incidence of eosinophilic neoplasms associated with rearrangements of PDGFRA, PDGFRB and FGFR1
The incidence rates for the molecularly defined eosinophilias are not known, nor are there data regarding the proportion of patients with hypereosinophilia represented by these genetically defined cases. With these caveats, eosinophilic MPNs with rearrangements of PDGFRA, PDGFRB and FGFR1 are considered to be very rare entities (for example, incidence o1/100 000 1. There is eosinophilia (eosinophil count 41.5 Â 10 9 /l) 2. There is no Ph chromosome or BCR-ABL fusion gene or other myeloproliferative neoplasms (PV, ET, PMF) or MDS/MPN (CMML or atypical CML) 3. There is no t(5;12)(q31-q35;p13) or other rearrangement of PDGFRB 4. There is no FIP1L1-PDGFRA fusion gene or other rearrangement of PDGFRA 5. There is no rearrangement of FGFR1 6. The blast cell count in the peripheral blood and bone marrow is less than 20% and there is no inv(16)(p13q22) or t(16;16)(p13;q22) or other feature diagnostic of AML 7. There is a clonal cytogenetic or molecular genetic abnormality, or blast cells are more than 2% in the peripheral blood or more than 5% in the bone marrow.
SPOTLIGHT

AML, acute myeloid leukemia; CEL, chronic eosinophilic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; HES, hypereosinophilic syndrome; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera. a Patients presenting with acute myeloid leukemia or lymphoblastic leukemia/lymphoma with eosinophilia and a FIP1L1-PDGFRA fusion gene are also assigned to this category. If appropriate molecular analysis is not available, this diagnosis should be suspected if there is a Ph-negative MPN with the hematological features of chronic eosinophilic leukemia associated with splenomegaly, a marked elevation of serum vitamin B12, elevation of serum tryptase and increased bone marrow mast cells. c Because t(5;12)(q31-q33;p12) does not always lead to an ETV6-PDGFRB fusion gene, molecular confirmation is highly desirable. If molecular analysis is not available, this diagnosis should be suspected if there is a Ph-negative MPN associated with eosinophilia and with a translocation with a 5q31-33 break point. Idiopathic hypereosinophilic syndrome is diagnosed when the following entities are excluded: reactive eosinophilia, lymphocyte-variant hypereosinophilia, chronic eosinophilic leukemia, NOS, clonal myeloid neoplasms-associated eosinophilia (criteria 2 above) and eosinophiliaassociated MPNs with rearrangements of PDGFRA, PDGFRB and FGR1. In addition, an eosinophil count of 41.5 Â 10 9 /l must persist for at least 6 months and tissue damage must be present. If there is no tissue damage, idiopathic hyerpeosinophilia is the preferred diagnosis.
Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools persons). When the original case series of Cools et al. 8 described the FIP1L1-PDGFRA fusion in 9 of 16 patients (56%) who were initially diagnosed as idiopathic HES or CEL, it was initially felt that the majority of patients would have their idiopathic hypereosinophilia explained by this cryptic molecular defect. However, the study was biased due to its preselected study population: patients were generally advanced cases for which other causes of hypereosinophilia had been thoroughly scrutinized, and they were being evaluated at tertiary referral centers by expert hematologists who were familiar with the clinical presentation of the myeloproliferative variant of HES with which the fusion ultimately segregated.
The median frequency of the FIP1L1-PDGFRA fusion in hypereosinophilia patients across eight published series enrolling more than 10 patients was 23% (range 3-56%) ( Table 2) . In a prospective, multicenter Italian study of 169 patients with eosinophilia, 72 were diagnosed with either primary eosinophilia or HES. Twenty-seven of the 63 patients who provided consent for testing were found to carry the FIP1L1-PDGFRA rearrangement (43%). 9 However, the incidence of the FIP1L1-PDGFRA fusion was only 16% of the 169 patients initially enrolled with a diagnosis of eosinophilia. Similarly, the fusion was found in only 40 of 376 individuals (11%) in a European trial of patients with persistent, unexplained hypereosinophilia. 10 In a Mayo series, 11 of 89 patients (12%) with moderateto-severe eosinophilia were FIP1L1-PDGFRA positive. 11 In a follow-up series of 714 unselected patients with eosinophilia, only 3% were fusion positive. 12 Additional studies are listed in Table 2 . [13] [14] [15] Despite these studies having their own selection biases, these data support a FIP1L1-PDGFRA fusion incidence of approximately 10-20% among patients presenting with idiopathic hypereosinophilia in developed countries.
In addition to the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusion genes, as well as different PDGFRB and FGFR1 fusion genes have been described in MPNs with eosinophilia. In the case of PDGFRA fusions, both the BCR-PDGFRA 16,17 and FIP1L1-PDGFRA 8, 18 fusions were identified in 2002-2003 as recurrent rearrangements, with the FIP1L1-PDGFRA fusion being the most common fusion. A few other variant PDGFRA fusion genes have now also been described (Table 3) . [19] [20] [21] In 1994, the group of Golub and Gilliland 22 described the ETV6-PDGFRB fusion as the first of these fusion genes in patients with chronic myelomonocytic leukemia with eosinophilia and t(5;12). Since then, a large variety of fusion partners for PDGFRB have been described, most of which, however, are single case reports (Table 4) . [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Despite the rare frequency (o1%) of PDGFRB rearrangements in cytogenetically defined cases of chronic myelomonocytic leukemia and other myeloid neoplasms (for example, atypical CML, juvenile myelomonocytic leukemia, chronic basophilic leukemia, myelodysplastic syndrome/MPN overlap), their recognition is essential given the exquisite sensitivity of such cases to imatinib.
Fusions involving the FGFR1 gene are similarly rare. The association of t(8;13)(p11;q11) with lymphoblastic lymphoma with eosinophilia and myeloid hyperplasia (for example, 8p11 myeloproliferative syndrome (EMS)) was initially described in 1995, followed by the discovery of the ZNF198-FGFR1 fusion gene in 1998 by four groups. [37] [38] [39] [40] Additional fusion partners for FGFR1, including BCR, have since been described (Table 5) . [41] [42] [43] [44] [45] [46] [47] The FGFR1 rearrangement can be found in both myeloid and lymphoid cells, suggesting an origin in a multipotent hematopoietic progenitor, and thus the basis for the disease's alternate designation of 'stem cell leukemia/ lymphoma syndrome.' EMS manifests an aggressive course and therefore early allogeneic transplantation is often recommended. Small molecule inhibition of the constitutively activated FGFR1 tyrosine kinase may also hold promise, as demonstrated in the case of a patient with a ZNF198-FGFR1 fusion who responded to PKC412. 48 Within all these different fusion genes, the FIP1L1-PDGFRA fusion is quite unique as it is generated by a cryptic chromosomal deletion, rather than a translocation. All other Table 2 Overview of selected molecular studies of HES/CEL that establish the frequency of the FIP1L1-PDGFRA fusion Abbreviations: CEL, chronic eosinophilic leukemia; HES, hypereosinophilic syndrome; NA, not available. Abbreviation: MPN, myeloproliferative neoplasm.
Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools PDGFRA, PDGFRB or FGFR1 fusions are generated by reciprocal translocations or by complex rearrangements, the latter usually being identified in single cases. Finally, in addition to rearrangements of PDGFRA, PDGFRB and FGFR1, the PCM1-JAK2 fusion gene was recently discovered in various eosinophilia-associated leukemias. The acquired JAK2 V617F mutation is found in 495% of patients with polycythemia vera, approximately 50% of patients with essential thrombocythemia or primary myelofibrosis and in a small proportion of patients with atypical myeloproliferative disorders. 49 The mutation results in constitutive activation of the tyrosine kinase, and transplantation of JAK2 V617F-transduced bone marrow to mice can recapitulate phenotypic aspects of human myeloproliferative disease including erythrocytosis, extramedullary hematopoiesis and bone marrow fibrosis. 49 In 2005, the PCM1-JAK2 fusion was identified as a second recurrent molecular abnormality, which results in dysregulation of JAK2 tyrosine kinase activity due to oligomerization mediated by the coiled-coil domains of PCM1. 50 The chimeric oncoprotein results from the t(8;9)(p22;p24) chromosomal translocation and may have pleiotropic clinical presentations, including atypical CML, AML, acute B-and T-cell lymphoblastic leukemias, often with peripheral eosinophilia. [50] [51] [52] [53] [54] The clinical course of the PCM1-JAK2 cases reported to date appears to be more aggressive than the JAK2 V617F-associated chronic MPDs. JAK2 inhibitors currently in phase I testing exhibit potential for treating these neoplasms characterized by constitutive JAK2 activation.
Biology of the FIP1L1-PDGFRa fusion
Mechanism of activation of the FIP1L1-PDGFRa tyrosine kinase
The structure of the FIP1L1-PDGFRa fusion protein resembles the structure of the ETV6-PDGFRb, ZNF198-FGFR1 and BCR-ABL proteins, for which homotypic oligomerization mediated by domains within ETV6, ZNF198 or BCR has been documented. [55] [56] [57] Oligomerization of the corresponding fusion proteins leads to activation of the tyrosine kinase domains, which in turn activate downstream signaling pathways regulating cell proliferation and survival. In contrast to this, we have been unable to demonstrate oligomerization of the FIP1L1-PDGFRa fusion protein. However, we have observed that interruption of the juxtamembrane of PDGFRa is indispensable for kinase activation in the context of FIP1L1-PDGFRa. 58 Indeed, it was previously shown that mutations or duplications within the juxtamembrane region of the PDGFR family of tyrosine kinases can cause constitutive activation of their kinase activity. 59 ,60 Not a chronic MPN, but diagnosed in a case of AML at relapse. 7 In addition, FGFR1 rearrangement has been found in association with t(8;12)(p11;q15) and t(8;17)(p11;q25) but the suspected involvement of FGFR1 in t(8;11)(p11;p15) was not confirmed.
SPOTLIGHT
Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools Also in cancer, this mechanism is well known from the internal tandem duplications in FLT3 and KIT in AML or gastrointestinal stromal tumors, respectively. 61, 62 Fusion of FIP1L1 to the PDGFRa protein yields a constitutive active tyrosine kinase only if the juxtamembrane domain of PDGFRa is partially or completely removed. 58 This is what happens in patients with the FIP1L1-PDGFRa fusion: there are very different break points within FIP1L1, but the break points within the PDGFRA gene are tightly clustered, invariably resulting in the removal of part of the juxtamembrane domain and activation of the kinase domain. A similar mechanism has now also been described in cases of the PRKG2-PDGFRb fusion, in which the break points in the PDGFRB gene are also within the juxtamembrane region. 63 In contrast, in other PDGFRb fusions, the juxtamembrane is completely intact, and in these fusions the activation of PDGFRb kinase activity is obtained through oligomerization mediated by the fusion partner ( Figure 1 ).
Role of FIP1L1
On the basis of the results described above, the role of the FIP1L1 part in the FIP1L1-PDGFRa fusion is less important than the role of ETV6 in the ETV6-PDGFRb fusion. Nevertheless, it is still the case that the FIP1L1-PDGFRA fusion gene is under control of the FIP1L1 promoter and translation start, and the FIP1L1 part in the fusion may determine the stability and subcellular localization of the fusion protein. Also, while FIP1L1 seems dispensable for transformation of Ba/F3 cells, Buitenhuis et al. 64 documented the differences in in vitro colony formation between FIP1L1-PDGFRA transduced CD34
þ cells and cells transduced by a deletion variant lacking part of FIP1L1.
Insights in the mechanism of FIP1L1-PDGFRA-induced eosinophilia FIP1L1-PDGFRa is required to stimulate proliferation and mediate survival of the eosinophils in CEL patients, through activation of several signaling pathways including phosphoinositol 3-kinase, ERK 1/2 and STAT5. 8, 64 The exact mechanism, however, by which FIP1L1-PDGFRa preferentially affects eosinophils remains unclear. The essential role of FIP1L1-PDGFRA is clear from in vitro studies with the EOL-1 cell line, from mouse models of FIP1L1-PDGFRA induced disease, and from the remarkable responses of FIP1L1-PDFGRA-positive CEL patients to imatinib treatment. 8, 18, 65, 66 The mouse model, however, has also suggested that expression of the FIP1L1-PDGFRA fusion is most likely not sufficient to cause eosinophilia, as mice expressing FIP1L1-PDGFRA in their bone marrow cells develop a general myeloproliferative disease without eosinophilia. 65 Expression of FIP1L1-PDGFRA together with overexpression of IL-5, however, mimics the disease much better in the mouse, with typical features of HES such as tissue infiltration of eosinophils. 67 Similarly, a study of polymorphic variation at the IL-5 receptor-a (IL5RA) gene revealed an association between a SNP in the 5 0 UTR of IL5RA and the eosinophil count/presence of tissue infiltration in FIP1L1-PDGFRA-positive HES patients. 68 These data suggest that FIP1L1-PDGFRA alone is not sufficient to explain the development of HES/CEL, and that additional factors such as IL-5 signaling may also be implicated or at least may influence the severity of the disease.
Detection of the FIP1L1-PDGFRA fusion and variant PDGFRA fusions
In many cases, patients expressing PDGFRA, PDGFRB, or FGFR1 fusion genes will have an abnormal karyotype indicating a rearrangement of 4q12 (PDGFRA), 5q31-33 (PDGFRB) or 8p11-12 (FGFR1). Therefore, an important message to hematologists is not to ignore karyotyping in cases with eosinophilia in order to rapidly identify patients with chromosomal rearrangements who may benefit from targeted therapy with specific kinase inhibitors. In addition to karyotyping, FISH analysis with probes flanking the PDGFRA, PDGFRB and FGFR1 genes remains valid in cases with obvious chromosomal rearrangements to confirm that the break points are indeed within these genes, as well as in cases without these specific rearrangements to check for possible cryptic rearrangements of these kinases. An important example of such cryptic rearrangement is the 4q12 deletion that causes the FIP1L1-PDGFRA fusion.
The generation of the fusion between the 5 0 part of the FIP1L1 gene and the 3 0 part of the PDGFRA gene occurs through an uncommon mechanism by which the 800 kb genomic region between the two genes is deleted (Figure 2) . 8 This deletion begins within the FIP1L1 gene, with variable break points in the different patients, and ends in exon 12 of PDGFRA. Owing to the fact that the deletion is only 800 kb in size, this genomic rearrangement remains undetectable by standard cytogenetics, but can be detected by FISH with specific probes. FISH probes that hybridize to the region between the FIP1L1 and PDGFRA genes are now commonly used to detect the presence of the deletion. As the CHIC2 gene is located in this region, this FISH test is sometimes referred to as 'FISH to detect the CHIC2 deletion.' 69 A more sensitive way to detect the presence of the FIP1L1-PDGFRA fusion gene in the blood of eosinophilia patients is the use of (nested) reverse transcription (RT)-PCR. Despite the fact that the break points in the FIP1L1 gene can be very different from patient to patient, a single primer combination is sufficient to detect the fusion transcript from most patients. In some patients, however, the fusion remains difficult to detect, which may be due to low-level expression of the fusion gene, heterogeneity in the FIP1L1 break points and difficulties with FISH in eosinophilia cases. Therefore, a combination of RT-PCR and FISH provides the best chance of identifying FIP1L1-PDGFRA-positive cases, and several groups are working on additional tests that could further limit the chances of false negative results. Despite some minor problems associated with RT-PCR to detect the FIP1L1-PDGFRA transcript, nested RT-PCR or quantitative RT-PCR remains the method of choice to monitor the response of the disease to therapy (see below). Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools
As a variety of PDGFRA and PDGFRB fusion genes involving partner genes other than FIP1L1 and ETV6 have also been detected in hypereosinophilia patients (Tables 3 and 4) , detection of these rare variants remains important, as these patients also benefit from imatinib treatment. These cases can be identified using specific primer sets for these fusions, or alternatively, can be identified using quantitative RT-PCR to detect increased levels of PDGFRA expression. 19 Disease phenotypes associated with FIP1L1-PDGFRA FIP1L1-PDGFRA is a clonal marker associated with the myeloproliferative variant of hypereosinophilia. 2, 8 These patients often present with organomegaly, hypercellular bone marrows with increased mast cells and/or myelofibrosis, increased serum tryptase levels, and historically carried a poor prognosis before the successful therapeutic application of imatinib. 2, 8, 13 Shortly, after its initial discovery in HES/CEL patients, the Mayo group linked the FIP1L1-PDGFRA fusion to pathologically confirmed cases of systemic mastocytosis with eosinophilia (SM-eo). 69 Histopathologically, the bone marrows of patients with FIP1L1-PDGFRA-positive SM-Eo exhibit less dense clusters of mast cells by tryptase immunostaining than are typically seen in SM, particularly cases with the common D816V KIT mutation. 11 However, in some cases of CEL with increased bone marrow mast cells, the mast cells may exhibit spindle-shaped morphology, form multifocal clusters and aberrant surface expression of CD25, major and minor criteria, which establish the basis for a WHO diagnosis of SM. Such cases may be considered a hybrid category of SM-CEL, wherein the CEL component is the associated hematologic non-mast cell lineage disease, pathogenetically driven by FIP1L1-PDGFRA. However, this may be an insufficient explanation as the FIP1L1-PDGFRA rearrangement has been found in a variety of myeloid cell types (neutrophils, monocytes, eosinophils), including mast cells, consistent with a mutational origin in a multipotent hematopoietic progenitor. 70 When clinical and pathologic features of CEL and SM co-exist in the same patient, it is certainly possible, if not likely, that both diseases originate from The consequence of the deletion at the DNA level is that a part of an intron of FIP1L1 (various introns possible) is directly fused to a piece of exon 12 of PDGFRA. To obtain splicing between FIP1L1 and PDGFRA, cryptic splice sites need to be used, as the normal splice site at the beginning of exon 12 is removed by the deletion. Dependent on the break points within FIP1L1 and PDGFRA, this cryptic splice site is either located within exon 12 of PDGFRA (type I fusion) or within the intron of FIP1L1 (type 2 fusion). In all cases, this 'abnormal' splicing results in the generation of in-frame fusion transcripts encoding catalytically active fusion proteins.
Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools the same clone. The relative 'penetrance' of eosinophil versus mast cell symptoms and organ involvement may be modified by host-or disease-related factors that have yet to be ascertained. The FIP1L1-PDGFRA fusion and D816V KIT appear to be mutually exclusive oncogenic mutations, as they have not been simultaneously reported in the same patient. Investigators from the NIH and Ann Arbor could reliably partition D816V KITpositive SM-Eo from FIP1L1-PDGFRA-positive CEL into clinically distinguishable entities based on several clinical and laboratory features. 71 In the D816V KIT-positive SM-Eo cohort, gastrointestinal symptoms, urticaria pigmentosa, thrombocytosis, the median serum tryptase value and the presence of dense mast cell aggregates in the bone marrow were statistically significantly elevated or more frequently represented compared to patients with FIP1L1-PDGFRA-positive CEL. Conversely, male sex, cardiac and pulmonary symptoms, median peak absolute eosinophil count, the eosinophil to tryptase ratio and serum B12 levels were significantly elevated or more frequently represented in the FIP1L1-PDGFRA-positive CEL group. A scoring system incorporating these clinical findings and laboratory tests was generated that could reliably predict the molecular status (D816V KIT versus FIP1L1-PDGFRA) of patients with peripheral eosinophilia and increased marrow mast cell burden. 71 More recently, the FIP1L1-PDGFRA fusion was also identified in five patients with AML (FAB subtypes M0, M2 and M4) and in two patients with lymphoblastic T-cell non-Hodgkin's lymphoma. 72 A search for the FIP1L1-PDGFRA rearrangement was prompted by the presence of eosinophilia either preceding or contemporaneous with the diagnosis of AML or T-NHL, or because eosinophilia persisted despite a complete hematologic remission after intensive chemotherapy. In the T-NHL cases, lymphoid involvement by FIP1L1-PDGFRA was confirmed by the presence of the CHIC2 deletion by FISH in CD3 þ T lymphocytes.
Clinical features
In the pre-fusion era, the cumulative frequencies of organspecific manifestations of HES were previously described in three case series. [73] [74] [75] In addition to universal involvement by the bone marrow, the most common organ systems involved included cardiac (58%), dermatologic (56%), neurologic (54%), pulmonary (49%), splenic (43%) and 20-30% involvement of the ocular and liver/gallbladder/GI systems. [73] [74] [75] [76] Although FIP1L1-PDGFRA-positive patients exhibit the previously alluded to myeloproliferative features, inconsistent reporting of their clinical features presentations makes comparisons to both historically described HES and FIP1L1-PDGFRA-negative patients challenging. In one larger series, less frequent lung and skin involvement, and more frequent splenomegaly characterized FIP1L1-PDGFRA-positive compared to FIP1L1-PDGFRAnegative cases of hypereosinophilia. 9 It is possible that a proportion of the fusion-negative patients may have represented lymphocyte-variant hypereosinophilia (not tested in the study), as such individuals have a high rate of cutaneous manifestations (pruritis, urticaria, angioedema, eczema, erythroderma).
Therapy
Imatinib therapy of FIP1L1-PDGFRA-positive CEL
The first report of imatinib treatment of HES was by Schaller and Burkland 77 in an online medical journal in 2001 (Table 6 ). Several case reports and small case series followed in [2001] [2002] , highlighting the dramatic hematological responses of patients with HES empirically treated with imatinib primarily in the dose range of 100-400 mg daily. [78] [79] [80] Complete and rapid hematologic remissions, with normalization of eosinophilia, were observed in a high proportion of patients.
The presence of a normal karyotype in responding patients implicated a subtle mutation or cryptic rearrangement of a Table 6 Different steps towards the discovery of the FIP1L1-PDGFRA fusion gene
SPOTLIGHT
2001:
Imatinib is approved for the treatment of BCR-ABL-positive CML.
2002: A patient with HES is being treated with imatinib. There is no good reason to try imatinib therapy for this patient, but he suffers from the side effects of other treatments. It is reasoned that HES resembles CML and that maybe imatinib could also be efficacious to treat HES. The patient shows a 'miraculous response' to imatinib, with complete resolution of symptoms and normal eosinophil levels reached within a few weeks of therapy. 
2002:
The kinase domains of PDGFRA, PDGFRB, ABL, and KIT are being sequenced to identify activating mutations in any of these kinases in HES patients with response to imatinib. No mutations are identified.
The study by the group of Gary Gilliland includes one HES/CEL patient with a t(1;4)(q44;q12) is included in the study. The 4q12 break point points towards a possible role of the PDGFRA gene in this rearrangement, but at this time it is not believed to be very important since this is not a general finding in all HES patients with response to imatinib. The molecular analysis of this translocation is started by FISH analysis to determine if the 4q12 break point is indeed within the PDGFRA gene.
May 2002:
The FISH for the 4q12 region with FISH probes flanking the PDGFRA gene show puzzling results: it is clear that PDGFRA is translocated to chromosome 1, but the probe upstream of PDGFRA (the CHIC2 locus) seems to be deleted. It is concluded that this could be a relatively complex rearrangement involving a partial deletion of chromosome 4. These data indicate that PDGFRA is likely to be involved in the rearrangement, and RACE analysis to identify the possible fusion partner of PDGFRA is started. June 2002: Analysis of the sequencing results of the RACE using BLAST suggest that a part of a gene on chromosome 4 is fused to PDGFRA, while a gene on chromosome 1 was expected. Initially these data seem a bit strange and disappointing: could it be an artifact of the PCR protocol? Then, upon more detailed analysis it is found that the fusion with the novel gene on chromosome 4 is a nice in-frame fusion with PDGFRA, and it is noted that this gene is only 800 kb upstream of PDGFRA. Now everything becomes clear: the FISH data indicated a deletion upstream of PDGFRA, the fusion that is identified could be generated by an 800 kb deletion on chromosome 4 fusing the novel gene to PDGFRA, andFmost importantlyFsuch small deletion would not be visible by standard karyotyping, and thus could be present in other HES patients with response to imatinib. July 2002: Long distance inverse PCR is performed on DNA samples from five additional HES patients and confirms the presence of similar deletions upstream of PDGFRA in four of the five patients. It is now clear that this deletion, leading to the generation of the FIP1L1-PDGFRA fusion, can explain many cases of 'idiopathic' HES, and the response of these patients to imatinib. 2002: At around the same time, researchers from Theravance Inc. observe that the EOL-1 cell line is sensitive to imatinib, and identify the FIP1L1-PDGFRa fusion protein in these cells using mass spectrometry. They confirm that the same fusion is present in HES patients.
March 2003 and June 2003:
The data from these studies are published.
8,18
Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools tyrosine kinase as the therapeutic target of imatinib, which was ultimately identified as FIP1L1-PDGFRa. 8, 18 Of the 16 HES/CEL patients enrolled in the study of Cools et al., 8 11 were treated with imatinib. Hematologic responses were observed in 10 of 11 HES patients treated with imatinib doses of 100-400 mg daily. The median time to response was 4 weeks (range 1-12 weeks). Nine of 10 patients demonstrated a durable hematologic response (lasting X3 months), with a median duration of 7 months at the time of publication. Now, more than 5 years later, the overwhelmingly majority of these patients remain in hematologic remission.
Numerous studies have since confirmed the hematologic benefit of imatinib in FIP1L1-PDGFRA-positive CEL. Similar to CML, sensitive real-time quantitative PCR-based assays are also used to follow in-depth molecular responses. Molecular remissions were first reported by the NIH group in five of six FIP1L1-PDGFRA-positive patients after 1-12 months of imatinib therapy. 81 Several additional reports have since described molecular remissions in imatinib-treated patients with FIP1L1-PDGFRA-positive disease or after bone marrow transplantation.
The natural history of imatinib-treated FIP1L1-PDGFRApositive CEL was recently reported by an Italian study which prospectively followed 27 patients (all male) for a median follow-up period of 25 months (range 15-60 months). 9 Patients were dose escalated from an initial dose of 100 mg daily to a final dose of 400 mg daily after the first month (median daily dose 339 mg). A complete hematologic remission was achieved in all patients within 1 month, and all patients became RT-PCR negative for the FIP1L1-PDGFRA fusion after 1-10 months of therapy (median 3 months). All 24 patients who continued imatinib therapy remained PCR negative during a follow-up period of 6-56 þ months (median 19 months).
Using real-time quantitative PCR, a European study prospectively assessed the natural history of molecular responses to imatinib (dose range100-400 mg daily) in 40 of 376 (11%) HES patients who were positive for the FIP1L1-PDGFRA fusion. 10 Fusion-positive patients exhibited higher absolute and % eosinophil counts compared to fusion-negative patients, but there was no correlation between the load of FIP1L1-PDGFRA expression and variables such as the white blood cell count, absolute or % eosinophil count, or % cells with the CHIC2 deletion by interphase FISH. A variability of up to 3 logs in the normalized FIP1L1-PDGFRA transcript load was found in patient samples before imatinib treatment. Among 11 patients with high pretreatment transcript levels, all achieved a 3-log reduction in transcript levels by 1 year of therapy, and 9 of 11 patients (82%) achieved a molecular remission.
It has now become clear that despite the in-depth and durable molecular responses with imatinib, discontinuation of the drug can lead to relapse. In the Italian study, three patients who discontinued imatinib after 12, 14 and 15 months of therapy experienced a rise in FIP1L1-PDGFRA transcript levels; upon restart of imatinib, fusion transcripts again became undetectable after 2-5 months of therapy. 9 In the European trial, withdrawal of imatinib in two patients was followed by a rapid rise in FIP1L1-PDGFRA fusion transcripts, with one of these patients achieving a second molecular remission after reinstitution of imatinib. 10 In a dose de-escalation trial of imatinib in five patients who had achieved a stable hematologic and molecular remission at 300-400 mg daily for at least 1 year, molecular relapse was observed in all patients: in one patient after 5 months of a reduced dose of 100 mg daily, and in four patients 2-5 months after discontinuation of drug. 82 Molecular remissions could be re-established with reinduction of imatinib in all cases at a dose range of 100-400 mg daily. Hematologic relapse was noted only several weeks after stoppage of imatinib in four patients in the Mayo series. 12 These data indicate that imatinib can suppress, but not eradicate the FIP1L1-PDGFRA clone, and that ongoing therapy is warranted. Although 100 mg daily may be sufficient to achieve a molecular remission in some patients, others may require higher maintenance doses in the range of 300-400 mg daily. However, in a recent series, maintenance dosing of 100-200 mg weekly was sufficient to sustain a molecular remission in five of six fusion-positive patients. 83 The ability of imatinib to produce a molecular remission may reflect differences in drug metabolism/absorption between individuals, disease burden and susceptibility of the various FIP1L1-PDGFRA breakpoints to the drug; however, the potential contributions of these factors have not been systematically analyzed.
Finally, it must also be noted that FIP1L1-PDGFRA fusion negative HES patients may benefit from imatinib therapy. In this group, however, hematologic responses tend to be partial, shortlived, and may reflect nonspecific drug-related myelosuppression. 8, 9 Alternatively, some of the cases with complete responses may be patients in which the PDGFRA or PDGFRB rearrangement remained undiscovered. It may thus be valid to try imatinib treatment in HES patients without detectable PDGFR rearrangements.
Safety issues of imatinib in FIP1L1-PDGFRA-positive disease
The safety profile of imatinib-treated patients with FIP1L1-PDGFRA-positive disease generally parallels that of CML. However, several cases of incipient cardiogenic shock have been reported in several FIP1L1-PDGFRA-positive patients after initiation of imatinib therapy. 84, 85 Endomyocardial biopsy revealed myocyte injury, likely an acute inflammatory response to imatinib resulting in degranulation of infiltrating eosinophils exacerbated by imatinib. Early use of high-dose corticosteroids led to the improvement of left ventricular dysfunction and clinical recovery. Currently, prophylactic use of steroids during the first 7-10 days of imatinib treatment is recommended for patients with known cardiac disease and/or elevated serum troponin T levels. 86 Resistance to imatinib in FIP1L1-PDGFRA-positive disease With more than 5 years of experience in the imatinib treatment of FIP1L1-PDGFRA positive disease, only four cases of acquired resistance have been reported. 8, 18, 86, 87 We identified the first case of imatinib resistance in a patient with advanced AML arising from CEL. 8 He exhibited the FIP1L1-PDGFRA fusion in addition to a complex karyotype. Despite a complete hematologic remission, the patient relapsed after 5 months of therapy, coinciding with the identification of a T674I mutation within the ATP-binding domain of PDGFRa. In agreement with this, Ba/F3 cells transformed by the FIP1L1-PDGFRa T674I mutant were 1000-fold more resistant to imatinib, compared to cells transformed by the wild-type fusion. 8 The observed acquired resistance in this CEL patient also confirmed that the FIP1L1-PDGFRa fusion protein was indeed the therapeutic target of imatinib. Additional cases of molecular resistance were similarly due to the PDGFRa T674I mutation, one in a patient with CEL evolving to myeloid blast crisis (also after 5 months after imatinib therapy), and one in a patient with Langerhans histiocytosis with eosinophilia treated with multiagent chemotherapy. 86 , 87 Recently, we observed the development of
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Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools resistance to imatinib in a fifth patient (Lierman E et al., unpublished data) . This patient presented with FIP1L1-PDGFRA-positive AML with eosinophilia, and developed imatinib resistance again due to the T674I mutation. Taken together, these data suggest that the T674I mutation is the most common, if not the only, mutation that may cause clinical resistance to imatinib in patients with FIP1L1-PDGFRA-positive acute leukemia. To date, resistance to imatinib has not been reported in cases with the chronic phase of eosinophilic leukemia. Acquired resistance to imatinib in FIP1L1-PDGFRAmediated disease is considerably rare compared to CML. It is unknown whether this relates to the 100-fold sensitivity of the FIP1L1-PDGFRA fusion to imatinib compared to the BCR-ABL tyrosine kinase or other biological properties of the FIP1L1-PDGFRA containing clone.
Treatment of imatinib-resistant FIP1L1-PDGFRa T674I: insights from preclinical studies
The FIP1L1-PDGFRa T674I mutation is analogous to the T315I BCR-ABL mutation in CML, which confers broad-spectrum resistance to the tyrosine kinase inhibitors imatinib, dasatinib and nilotinib. 88 We tested several known PDGFR inhibitors for their activity against the imatinib-resistant T674I mutant form of FIP1L1-PDGFRa using a cellular screen in Ba/F3 cells (Table 7) . PKC412, a potent FLT3 inhibitor that is in clinical development for the treatment of AML, was the first inhibitor to be identified with activity against the FIP1L1-PDGFRa T674I mutant. 65 Using both in vitro and in vivo mouse models, we demonstrated the ability of PKC412 to induce apoptosis in FIP1L1-PDGFRa T674I-transformed cells, and to significantly reduce leukocytosis and splenomegaly in a FIP1L1-PDGFRa T674I mouse model. 65 In a second study, we identified sorafenib, a BRAF and VEGFR inhibitor approved for the treatment of renal cell carcinoma, as another potent inhibitor of both FIP1L1-PDGFRa and the T674I mutant form. 89 In addition, nilotinib was also shown to have some activity towards both FIP1L1-PDGFRa and the T674I mutant. 90, 91 These data show that several small molecule kinase inhibitors are already available to treat FIP1L1-PDGFRApositive patients who develop resistance to imatinib.
Conclusions
Increasing recognition of eosinophilia-associated cytogenetic and molecular abnormalities, in conjunction with the advent of targeted small molecule inhibitors, has resulted in substantial benefit for patients affected by these MPNs. However, to reap the benefits of this success, it is critical that clinicians test for the occult FIP1L1-PDGFRA fusion in the context of undiagnosed hypereosinophilia and recognize hallmark translocations involving 5q31Bq33, 4q12, 8p13 and 9p24, as these may represent 'druggable' molecular rearrangements (for example, PDGFRB, PDGFRA, FGFR1 and JAK2, respectively). Ongoing work is aimed at identifying the molecular basis for patients with idiopathic hypereosinophilia and developing tyrosine kinase inhibitors with activity against MPNs with rearranged FGFR1 and JAK2. Fortunately, 5 years after the discovery of FIP1L1-PDGFRA, acquired resistance to imatinib has been a rare problem. Table 7 Most important inhibitors for treatment of FIP1L1-PDGFRA-positive CEL Five years since the discovery of FIP1L1-PDGFRA J Gotlib and J Cools
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